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MaOBJECTIVES This study examined whether coronary angioscopy-veriﬁed in-stent yellow plaque at 1 year after drug-
eluting stent (DES) implantation is associated with future event of very late stent failure (VLSF).
BACKGROUND Atherosclerosis detected as yellow plaque by angioscopy has been associated with future events of
acute coronary syndrome. Development of in-stent neoatherosclerosis is a probable mechanism of VLSF.
METHODS This study included 360 consecutive patients who received successful angioscopic examination at 1 year
after implantation of a DES. They were clinically followed up for VLSF deﬁned as cardiac death, acute myocardial
infarction or unstable angina, or need for revascularization associated with the stent site.
RESULTS The follow-up interval was 1,558  890 days (4.3  2.4 years). The incidence of VLSF was signiﬁcantly higher
in the patients with yellow plaque than in those without (8.1% vs. 1.6%; log rank p ¼ 0.02). Multivariable analysis
revealed the presence of yellow plaque (hazard ratio [HR]: 5.38; p ¼ 0.02) and absence of statin therapy (HR: 3.25;
p ¼ 0.02) as risks of VLSF.
CONCLUSIONS In-stent atherosclerosis evaluated by yellow plaque at 1 year after the implantation of DES and the
absence of statin therapy were risks of VLSF. The underlying mechanism of VLSF appeared to be the progression of
atherosclerosis as demonstrated by the yellow plaque. (J Am Coll Cardiol Intv 2015;8:814–21) © 2015 by the American
College of Cardiology Foundation.A lthough introduction of drug-eluting stent(DES) use substantially reduced early targetlesion revascularization (TLR) as compared
to bare-metal stent use by restricting development
of neointima hyperplasia, DES have been associated
with increased the risk of stent thrombosis and TLR
after 1 year, that is, very late stent failure (VLSF) (1).
The incidence of VLSF has been reduced with the
use of newer DES than with ﬁrst-generation DES
(2–8), but VLSF remains an unresolved problemm the Cardiovascular Division, Osaka Police Hospital, Osaka, Japan. The a
evant to the contents of this paper to disclose.
nuscript received August 9, 2014; revised manuscript received Decemberassociated with DES and its mechanism is not well
understood.
Although coronary angioscopy has not become
a mainstream intravascular imaging technique, it
has provided substantial information pertaining to
macroscopic pathology in living patients. It has
reliably detected atherosclerosis as yellow plaques,
and especially those with high-grade yellow color
have been regarded high-risk plaques and demon-
strated to be associated with future coronary eventsuthors have reported that they have no relationships
5, 2014, accepted December 18, 2014.
AB BR E V I A T I O N S
AND ACRONYM S
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
HR = hazard ratio
SES = sirolimus-eluting
stent(s)
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815by many clinical studies (9–12). Neoatherosclerosis
or atherosclerosis progression has been proposed
to be associated with VLSF (13). In the present
prospective follow-up study, we examined whether
the presence of in-stent yellow plaque at 1 year
after DES implantation would predict the risk
of subsequent VLSF associated with the original
stent site.TABLE 1 Patient Characteristics
All
(n ¼ 360)
YP
(n ¼ 235)
No YP
(n ¼ 125) p Value
Male 297 (83) 195 (83) 102 (82) 0.7
Age, yrs 66  9 66  8 67  10 0.1
Risk factor
Diabetes mellitus 148 (41) 92 (39) 56 (45) 0.3
Hypertension 303 (84) 193 (82) 110 (88) 0.1
Hypercholesterolemia 313 (87) 202 (86) 111 (89) 0.5
Current smoking 57 (16) 39 (17) 18 (15) 0.6
Body mass index 25  3 25  3 25  4 0.1
Diagnosis for stenting 0.5
ACS 62 (17) 43 (18) 19 (15)
Non-ACS 298 (83) 192 (82) 106 (85)
Target vessel 0.4
Left anterior descending coronary artery 166 (46) 100 (43) 66 (53)
Left circumﬂex coronary artery 53 (15) 36 (15) 17 (14)
Right coronary artery 141 (39) 99 (42) 42 (33)
Stent type <0.001
Cypher SES 224 (62) 163 (69) 61 (49)
Taxus PES 68 (19) 36 (15) 32 (26)
Endeavor ZES 18 (5) 6 (3) 12 (10)
Xience EES 39 (11) 21 (9) 18 (14)
Nobori BES 11 (3) 9 (4) 2 (2)
Stent diameter, mm 3.0  0.4 3.0  0.4 3.0  0.3 0.1
Total stent length, mm 26  15 27  16 25  12 0.2
Serum lipid proﬁle, mg/dl
Total cholesterol 180  33 182  34 176  32 0.1
Low-density lipoprotein cholesterol 99  30 102  31 95  28 0.04
High-density lipoprotein cholesterol 49  12 50  12 48  13 0.1
Triglycerides 157  112 151  98 169  134 0.1
Angioscopic ﬁnding
Yellow plaque 235 (65) 235 (100) 0 (0) N/A
Thrombus 99 (28) 82 (35) 17 (14) <0.001
Minimal neointima coverage grade 0.5  0.6 0.5  0.5 0.6  0.6 0.6
Minimal neointima coverage grade 1.6  0.5 1.6  0.5 1.5  0.5 0.9
Medication
Statin 267 (74) 173 (74) 94 (75) 0.8
Aspirin 338 (94) 220 (94) 118 (94) 0.8
Clopidogrel/ticlopidine 307 (85) 196 (83) 111 (89) 0.2
Values are n (%) and mean  SD.
ACS ¼ acute coronary syndrome(s); BES ¼ biolimus-eluting stent(s); EES ¼ everolimus-eluting stent(s);
N/A ¼ not applicable; PES ¼ paclitaxel-eluting stent(s); SES ¼ sirolimus-eluting stent(s); YP ¼ yellow plaque;
ZES ¼ zotarolimus-eluting stent(s).
SEE PAGE 822 TLR = target lesion
revascularization
VLSF = very late stent failure
ZES = zotarolimus-eluting
stent(s)METHODS
STUDY DESIGN. We performed a single-center pro-
spective follow-up study (DESNOTE [Detect the Event
of Very Late Stent Failure From the Drug-Eluting
Stent Not Well Covered by Neointima Determined
by Angioscopy]) to demonstrate that the angioscopic
ﬁndings of the stented segment, especially the pres-
ence of in-stent yellow plaque, at 1 year after DES
implantation would be at risk of future VLSF.
All patients who received successful angioscopic
examination at planned 1-year follow-up after the
DES implantation in the native coronary artery
without any event of earlier stent failure were
enrolled from July 20, 2004 to August 8, 2013 and
clinically followed up for the occurrence of VLSF.
Yellow color, neointima coverage, and thrombus at
the site of DES implantation were examined by
angioscopy. VLSF was deﬁned as follows: 1) cardiac
death; 2) myocardial infarction or unstable angina at
the target stent; or 3) TLR at the target stent. Written
informed consent was obtained from all enrolled pa-
tients. Although angioscopic examination at 1-year
follow-up was encouraged for all patients who
received DES at our hospital, it was not performed in
the following situations: 1) when an angioscopic
specialist was not available; 2) when there was not
adequate time for the examination; or 3) when the
informed consent could not be obtained.
Catheterization was performed by femoral,
brachial, or radial artery approach using a 6-F or 7-F
sheath and catheters. Coronary angiogram was
recorded by the Innova Cardiovascular imaging sys-
tem (GE Healthcare Japan, Tokyo, Japan). Glycopro-
tein IIb/IIIa inhibitors were not used because they
were not approved in Japan for clinical use. Cypher
sirolimus-eluting stent (SES) (Cordis, Bridgewater,
New Jersey) and Taxus paclitaxel-eluting stent (Bos-
ton Scientiﬁc, Natick, Massachusetts) were deﬁned as
the ﬁrst-generation DES, and the other DES used were
deﬁned as second-generation DES.
The data on the patient demographics were ac-
quired from the clinical record at the time ofenrollment for the angioscopic examination
(Table 1). Some data on the patient back-
ground were additionally acquired at the end
of follow-up. Lipid proﬁle was recorded with
low-density lipoprotein cholesterol calcu-
lated from high-density lipoprotein choles-
terol and triglyceride levels. Hypertension
was deﬁned as the blood pressure >140/90
mm Hg or current antihypertensive drug use.
Diabetic patients were deﬁned as the patients
with fasting blood glucose >126 mg/dl or
those already taking oral drugs for diabetes
FIGURE 1 A Case o
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816mellitus or receiving insulin therapy. Acute coronary
syndrome included acute myocardial infarction with
or without ST-segment elevation deﬁned by the Joint
European Society of Cardiology/American College of
Cardiology Committee and unstable angina was
deﬁned according to the Braunwald classiﬁcation.
This study was approved by the Osaka Police Hospital
Ethical Committee.
ANGIOSCOPIC EXAMINATION AND EVALUATION.
The RX-3310A and MV-5010A nonobstructive coro-
nary angioscopes (Machida, Tokyo, Japan) and
DAG-2218 LN optic ﬁber (Machida) were used.
Angioscopic observation of the stented lesions was
done while blood was cleared away from the viewing
area by the injection of 3% dextran-40 as we previ-
ously reported (14). Yellow color was classiﬁed into 4
grades (0: white, 1: slight yellow, 2: yellow, and 3:
intensive yellow) compared with the standard colors
as we previously reported (9,10). Neointima coverage
was classiﬁed into 3 grades (0: no coverage, 1: poor
coverage, 2: complete coverage) as we previously
reported (15,16). Thrombus was deﬁned as white orf the Patient With Yellow Plaque Who Experienced VLSF
patient who had been treated by Cypher sirolimus eluting stent for
received 1-year follow-up catheterization. Angiography (A) revealed
is in the circumﬂex coronary artery and angioscopy (B) detected
stent (red arrow). The yellow line indicates the segment where the
. The patient experienced recurrence of effort angina at 23 months
xamination and received catheterization again. Then, angiography (C)
tenosis especially at the site where yellow plaque had been detected
red arrow). VLSF ¼ very late stent failure.red material that had cotton-like or ragged appear-
ance or that presented fragmentation with or without
protrusion into lumen or adherent to the luminal
surface. Maximum and minimum neointima coverage
grade, maximum yellow color grade, and presence or
absence of thrombus was determined for each stented
lesion. Presence of yellow plaque was deﬁned as the
maximum yellow color grade $2. Two specialists of
angioscopy, who were blinded to patients’ charac-
teristics, evaluated the angioscopic images. In the
case of disagreement, a third reviewer served as an
arbitrator. The inter observer and intraobserver
reproducibility for the interpretation of angioscopic
images (16) was 95% and 95% for stent coverage, 85%
and 95% for plaque color, and 90% and 100% for
thrombus, respectively.
STATISTICAL ANALYSIS. Continuous data were pre-
sented as mean  SD. Patients were divided into 2
groups according to the presence or absence of yellow
plaque at the site of stent implantation. Comparisons
between the groups were performed by unpaired
Student t-test or chi-square test. The incidence of
VLSF was compared between the groups using
Kaplan-Meier methods and log rank test. Multivari-
able Cox proportional hazards regression analysis was
performed to determine the risk factors of VLSF; the
variables included were as follow: stent type (ﬁrst vs.
second generation); age; sex; hypertension; diabetes
mellitus; current smoking; stenting for acute coro-
nary syndrome; serum low-density lipoprotein
cholesterol; serum high-density lipoprotein choles-
terol; serum triglyceride; aspirin use; ticlopidine/
clopidogrel use; statin use; stent diameter; total stent
length; presence of yellow plaque; presence of
thrombus; and minimum neointima coverage grade.
Proportionality assumptions were tested by graphic
approaches. A p value of <0.05 was regarded as sta-
tistically signiﬁcant. Analysis was performed with
SPSS (version 16.0 J for Windows, SPSS Inc., Chicago,
Illinois).
RESULTS
PATIENTS’ CHARACTERISTICS. During the study
period, 360 patients were enrolled, and 235 (65%) of
them had yellow plaque. The follow-up interval was
1,558  890 days (4.3  2.4 years). The patient de-
mographics presented in Table 1 compare patients
with and without yellow plaque. The patient charac-
teristics were similar between the groups except that
the distribution of stent type was different, and that
serum low-density lipoprotein cholesterol was higher
and the frequency of thrombus was higher in the
FIGURE 2 Kaplan-Meier Analysis on the Incidence of VLSF
The incidence of very late stent failure (VLSF) was signiﬁcantly higher in the patients
with in-stent yellow plaque than in those without during the follow-up interval of
1,558  890 days (4.3  2.4 years) (8.1% vs. 1.6%; log rank p ¼ 0.029).
TABLE 2 Incidence of Primary Endpoint and its Components
All YP No YP p Value
Primary endpoint 21 (5.8) 19 (8.1) 2 (1.6) 0.01
Combination of cardiac death, acute myocardial
infarction, and unstable angina
11 (3.1) 10 (4.3) 1 (0.8) 0.07
Components of primary endpoint
Cardiac death 5 (1.4) 5 (2.1) 0 (0) 0.1
Acute myocardial infarction 3 (0.8) 2 (0.9) 1 (0.8) 0.9
Unstable angina 3 (0.8) 3 (1.3) 0 (0) 0.2
Target lesion revascularization 15 (4.2) 14 (6.0) 1 (0.8) 0.02
Values are n (%).
YP ¼ yellow plaque.
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817patients with yellow plaque than in those without.
A case of the patient with yellow plaque who expe-
rienced VLSF is presented in Figure 1.
INCIDENCE OF VLSF. The incidence of VLSF was
signiﬁcantly higher in the patients with in-stent yel-
low plaque than in those without during the follow-
up interval of 4.3  2.4 years (8.1% vs. 1.6%; log
rank p ¼ 0.02) (Figure 2). The incidence of VLSF and
TLR were both signiﬁcantly higher in the patients
with yellow plaque than in those without, although
the incidence of cardiac death, acute myocardial
infarction, unstable angina, and the combination of
cardiac death, acute myocardial infarction, and un-
stable angina were not signiﬁcantly different between
the groups (Table 2). The sensitivity, speciﬁcity,
positive predictive value, and negative predictive
value of yellow plaque for VLSF were 90.5%, 36.3%,
8.1%, and 98.4%, respectively.
RISK FACTORS FOR THE OCCURRENCE OF VLSF.
Multivariable Cox regression analysis revealed that
presence of yellow plaque, absence of statin therapy,
smaller stent diameter, and serum low-density lipo-
protein cholesterol level were signiﬁcantly correlated
to VLSF risk (Table 3).
ADDITIONAL ANALYSIS USING THE DATA AT THE
END OF FOLLOW-UP. The serum lipid proﬁle and
medications at the end of follow-up were collected
from the clinical record (Table 4). The serum low-
density lipoprotein cholesterol was still signiﬁcantly
higher in the patients with yellow plaque. Multi-
variable Cox regression analysis using these data
revealed that the presence of yellow plaque and the
increase in the serum low-density lipoprotein
cholesterol level from baseline to the end of
follow-up were the signiﬁcant risk factors for VLSF
(Table 5).
DISCUSSION
We observed a signiﬁcant association between the
angioscopic ﬁndings of yellow plaque in the DES-
implanted lesion at 1 year after implantation and the
subsequent VLSF. The incidence of VLSF was signif-
icantly higher in the patients with yellow plaque than
in those without during the follow-up period of more
than 4 years; a multivariable analysis demonstrated
presence of yellow plaque (hazard ratio [HR]: 5.38;
p ¼ 0.02) and absence of statin therapy (HR: 3.25; p ¼
0.02) as risks of VLSF. Because statin therapy is
known to reduce the yellow color of plaques, these
ﬁndings suggest that the progression of yellow plaque
would be an important mechanism for the occurrenceof VLSF. This is the ﬁrst study that linked angioscopic
identiﬁcation of in-stent yellow plaque to actual hard
events of VLSF.
YELLOWPLAQUEFORMATIONAFTERDES IMPLANTATION.
Higo et al. (15) had originally reported that in living
humans Cypher-SES accelerated the formation of
yellow plaque at 10 months after implantation.
A recent histopathologic study by Nakazawa et al.
(13) conﬁrmed the presence of neoatherosclerosis
after bare-metal stent and DES implantation with
TABLE 3 Multivariable Cox Regression Analysis To Evaluate the Risk
Factors of VLSF
HR (95% CI) p Value
Presence of yellow plaque 5.38 (1.24–23.3) 0.02
Without statin use 3.25 (1.18–8.92) 0.02
Stent diameter, mm 0.27 (0.08–0.90) 0.03
Low-density lipoprotein cholesterol, mg/dl 0.97 (0.96–0.99) <0.001
Stent type (ﬁrst vs. second generation), age, sex, hypertension, diabetes mellitus, current
smoking, stenting for acute coronary syndrome, serum low-density lipoprotein cholesterol, serum
high-density lipoprotein cholesterol, serum triglyceride, aspirin use, ticlopidine/clopidogrel use,
statin use, stent diameter, total stent length, presence of yellow plaque, presence of thrombus,
and minimum neointima coverage grade were included as variables.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
TABLE 4 Patients’ C
Serum lipid proﬁle, mg
Low-density lipoprot
High-density lipopro
Triglycerides
Low-density lipoprot
High-density lipopro
Triglyceride change*
Medication
Statin
Aspirin
Clopidogrel/ticlopidi
Values are mean  SD or n
YP ¼ yellow plaque.
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818the shorter implantation duration for DES to de-
velop neoatherosclerosis. Cypher SES is known
to accelerate the formation of yellow plaque;
Xience everolimus-eluting stent (EES) (Abbott
Vascular, Santa Clara, California) does not change the
yellow color of the stented lesion; and Endeavor
zotarolimus-eluting stent (ZES) (Medtronic, Minne-
apolis, Minnesota) (17) leads to formation of thick
ﬁbrous white neointima similar to BMS. The forma-
tion of thick ﬁbrous white neointima over athero-
sclerotic yellow lesions might contribute to stability
of plaques. Xience EES has a very thin neointima and
may not shield the yellow plaque under the stent;
however, it does not accelerate the formation of
yellow plaque.
Yellow plaque formation could be accelerated by
various coronary risk factors and reduced by medical
therapy like statins. Therefore, in combination with
these systemic factors and medications, the charac-
teristics of each DES may inﬂuence the formation of
yellow plaque at the stent site.haracteristics at the End of Follow-Up
All YP No YP p Value
/dl
ein cholesterol 87  26 90  28 81  22 0.003
tein cholesterol 46  13 47  12 45  13 0.1
138  91 137  76 139  115 0.8
ein cholesterol change* 12  31 11  34 13  24 0.6
tein cholesterol change* 3  9 3  9 3  9 0.7
20  94 14  87 31  106 0.1
279 (78) 183 (78) 96 (77) 0.8
323 (90) 213 (91) 110 (88) 0.4
ne 247 (69) 159 (68) 88 (70) 0.6
(%). *Change from baseline to the end of follow-up.INCIDENCE OF VLSF IN VARIOUS CLINICAL TRIALS.
According to the results of clinical trials with up
to 5-year follow-up available in previous reports and
at ClinicalTrial.gov, TLR rates at 1 and 5 years are
4.9% and 9.4% in Cypher SES (18,19); 4.4% and
9.1% in Taxus paclitaxel-eluting stents (20,21); 5.9%
and 7.5% in Endeavor ZES (22,23); and 3.4% and
8.9% in Xience EES (24), respectively. The VLSF as
shown by the yearly TLR between 1 and 5 years is
1.1%, 1.2%, 0.4%, and 1.4% per year in Cypher SES,
Taxus paclitaxel-eluting stents, Endeavor ZES, and
Xience EES, respectively, which favors Endeavor
ZES as the DES to use. A recent report (3) clariﬁed
that, in the ENDEAVOR III (A Randomized
Controlled Trial of the Medtronic Endeavor Drug
[ABT-578] Eluting Coronary Stent System Versus the
Cypher Sirolimus-Eluting Coronary Stent System in
De Novo Native Coronary Artery Lesions), although
higher angiographic restenosis was observed with
Endeavor ZES than with Cypher SES at 9 months,
cumulative outcomes through 5 years demonstrated
that the composite endpoint of MACE, cardiac
death, and myocardial infarction, were lower with
Endeavor ZES use than with Cypher SES use.
Furthermore, the rate of TLR beyond 9 months was
signiﬁcantly lower in Endeavor ZES than with
Cypher SES. The higher incidence of VLSF with
Cypher SES than with Endeavor ZES may possibly
be explained by the fact that Cypher SES increases
the yellow color of the lesion and Endeavor ZES
reduces it.
ASSOCIATION BETWEEN ANGIOSCOPIC FINDINGS
AND FUTURE EVENTS OF VLSF. Development of
neoatherosclerosis has been proposed as a cause of
very late stent thrombosis (25) and of restenosis after
DES implantation (26). As demonstrated in the pre-
sent analysis, the presence of yellow plaque at 1 year
was a signiﬁcant risk of future VLSF, although the
presence of thrombus or the minimum neointima
coverage grade was not detected as a signiﬁcant risk.
The absence of statin therapy also presented
a signiﬁcant risk, suggesting that prevention of
atherosclerosis progression would be an important
mechanism for the prevention of VLSF. This is
consistent with a report from the CREDO-Kyoto Reg-
istry Cohort 2 (Comparison of three-year outcome
after PCI and CABG stratiﬁed by the SYNTAX score in
patients with triple vessel coronary artery disease:
an observation from the CREDO-Kyoto PCI/CABG
registry Cohort-2) that statin use was associated with
the lower risk of late TLR after Cypher SES implan-
tation (27). Being consistent with a previous report
(28), the smaller stent diameter was also a risk for
TABLE 5 Multivariable Cox Regression Analysis To Evaluate the
Risk Factors of VLSF Including the Data at the End of Follow-Up
HR (95% CI) p Value
Presence of yellow plaque 8.55 (1.13–66.7) 0.03
Low-density lipoprotein cholesterol
change from baseline to the end
of follow-up, mg/dl
1.03 (1.01–1.04) 0.001
Low-density lipoprotein cholesterol
at the end of follow-up, mg/dl
0.98 (0.97–1.00) 0.07
Stent diameter, mm 0.28 (0.08–1.00) 0.05
Stent type (ﬁrst vs. second generation), age, sex, hypertension, diabetes mel-
litus, current smoking, stenting for acute coronary syndrome, serum low-density
lipoprotein cholesterol, serum high-density lipoprotein cholesterol, serum tri-
glyceride, serum low-density lipoprotein cholesterol change from baseline to
follow-up, serum high-density lipoprotein cholesterol change from baseline to
follow-up, serum triglyceride change from baseline to follow-up, aspirin use,
ticlopidine/clopidogrel use, statin use, stent diameter, total stent length,
presence of yellow plaque, presence of thrombus, and minimum neointima
coverage grade were included as variables.
Abbreviations as in Table 3.
FIGURE 3 Correlation Between the LDL-C at Baseline and Its
Change by Follow-Up
The value of low-density lipoprotein cholesterol (LDL-C)
measured at the time of angioscopic examination (baseline) was
inversely correlated with its change by the time of follow-up
(R ¼ 0.63; p < 0.001). Therefore, the patients with the higher
LDL-C level at baseline possibly achieved the lower risk of VLSF.
The higher the value, the patient and doctor might have made a
stronger effort to reduce it.
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819VLSF in the present study. Although it appeared
strange that the higher low-density lipoprotein
cholesterol was associated with the lower risk of
VLSF, it might be explained by the fact that the value
of low-density lipoprotein cholesterol used in the
multivariable analysis was measured at the time of
angioscopic examination and that the higher value
was reduced more by the end of clinical follow-
up (R ¼ 0.63; p < 0.001) (Figure 3), possibly
achieving the lower risk of VLSF. The higher the
value, both the patient and doctor might have made
a stronger effort to reduce it. When the data at the
end of follow-up were included in the multivariable
analysis, the presence of yellow plaque and the
increase in the serum low-density lipoprotein
cholesterol level from baseline to the end of follow-
up were selected as being at signiﬁcant risk of
VLSF. This suggests that the extent of baseline in-
stent atherosclerosis and its progression induced
by increased serum low-density lipoprotein choles-
terol level might have determined the occurrence
of VLSF.
ATHEROSCLEROSIS DEFINED BY YELLOW PLAQUE
EVALUATED BY ANGIOSCOPIC STUDIES. Angioscopically
detected yellow plaque has been commonly detected
at the culprit lesions of spontaneous acute coronary
syndrome (10). Yellow plaques, especially those with
high yellow color grade, are regarded as vulnerable
plaques, because they have high prevalence of
disruption-causing thrombus formation and because
they have thin ﬁbrous caps (9,29). The patients with
more yellow plaques in their coronary arteries have
been demonstrated to have higher risk of future
acute coronary syndrome by a prospective study (30).Like the culprit lesions of spontaneous acute coro-
nary syndrome, the culprit lesions of very late stent
thrombosis are known to have disrupted yellow pla-
que (31). Furthermore, the culprit lesions of both
thrombosis and restenosis in the very late phase
after stent implantation have been reported by
angioscopic and optical coherence tomography
studies to have advanced atherosclerosis (11,32,33).
Therefore, the results of DESNOTE study are very
important and informative, which have demon-
strated that having yellow plaque at the site of stent
implantation is a risk of future VLSF, suggesting
that regression of yellow plaque by statin or other
antiatherosclerotic therapy may be an effective
treatment to prevent VLSF. Furthermore, the intra-
coronary imaging at 1 year after implantation of
DES may identify the risk of future VLSF before the
long-term clinical data become available. We would
like to emphasize again that this is the ﬁrst study
to link angioscopic identiﬁcation of in-stent yellow
plaque to the actual hard events of VLSF in the
future.
STUDY LIMITATIONS. Although we included all
types of DES available, more ﬁrst-generation DES
were included than the newer DES during the study
period. The data on the newer DES may become
available in the future. Although the patients with
PERSPECTIVES
WHAT IS KNOWN? The ﬁndings of neoatheroscle-
rosis are often detected at the sites of DES failure.
However, its correlation to the occurrence of future
event is unknown.
WHAT IS NEW? This study demonstrated that the
in-stent atherosclerosis evaluated by yellow plaque at
one year after the implantation of DES and the
absence of statin therapy were the risks of very-late
DES failure, suggesting that the underlying mecha-
nism of very-late DES failure appeared to be the
progression of atherosclerosis as demonstrated by the
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820tortuous or small vessels not suitable for angioscopic
examination or those with renal dysfunction were
not excluded, they were unlikely to be included.
The number of patients included was too small for
the more detailed subanalysis. Indeed, among the
components of primary endpoints, only TLR was
signiﬁcantly different between the groups, whereas
the study at this time point might be underpowered
to clarify whether the other components were truly
different. With a larger study population and longer
follow-up interval, this study will clarify these
questions in the future. Angioscopy could not ac-
quire the images of whole vessel wall due to the
blood ﬂow and might have missed some yellow
plaques.yellow plaque.
WHAT IS NEXT? Because the presence of in-stent
atherosclerotic yellow plaque at one year after the
implantation of DES and the absence of statin therapy
were identiﬁed in this study as the risk of future DES
failure, the medical treatments to prevent the forma-
tion of atherosclerotic yellow plaque would be ex-
pected to reduce the risk of DES failure. Therefore, the
statin therapy and other anti-atherosclerotic therapies
would be recommended for the prevention of very-
late DES failure. Large randomized trials are required
to test if the aggressive anti-atherosclerotic therapies
can really reduce the incidence of very-late DES failure.CONCLUSIONS
In-stent atherosclerosis evaluated by the presence of
yellow plaque at 1 year after the implantation of DES
and the absence of statin therapy was demonstrated
as a risk of VLSF. A main mechanism of VLSF was
suggested to be the progression of atherosclerosis as
shown by yellow plaque.
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